Cart summary

You have no items in your shopping cart.

Morusin

SKU: orb1221943

Description

Morusin possesses antitumor effects of cell lines including HT-29, A549, MCF-7, and MDA-MB-231, through suppressing STAT3 and NFκB attenuation mediated apoptosis induction. Morusin possesses anti-oxidant and anti-inflammatory effects.

Images & Validation

Key Properties

CAS Number62596-29-6
MW420.46
Purity>98% (HPLC)
FormulaC25H24O6
SMILESCC(=CCC1=C(OC2=C3C=CC(OC3=CC(=C2C1=O)O)(C)C)C4=C(C=C(C=C4)O)O)C
TargetSTAT3|NF-Κb
SolubilityDMSO : ≥ 125 mg/mL; 297.30 mM

Bioactivity

In Vivo
Morusin retards the growth of breast cancer significantly. Mean tumor weight of the control mice is 1.14±0.30 g, and those of the mice administrated with 5 and 10 mg/kg of morusin are 0.61±0.23 and 0.41±0.10 g, respectively, tumor inhibitory rates are 46.5 %, and 64.1 %, respectively.
In Vitro
Morusin exhibits a dose- and time-dependent inhibitory effect on murine and human breast cancer cells. IC50 is 9.48 μg/mL for normal mammary epithelial cells (MCF-10A); 2.03 and 1.87 μg/mL for murine breast cancer cells (4 T1 and EMT6); and 2.71 and 3.86 μg/mL for human breast cancer cells (MCF-7 and MDA-MB-231), respectively, the maximal inhibition of cell growth (> 80%) is obtained at 8 μg/mL. The apoptotic cells in morusin treated breast cancer cells are increased significantly in a dose-dependent manner. Morusin significantly inhibits the growth and clonogenicity of human colorectal cancer HT-29 cells. Morusin also inhibits the phosphorylation of IKK-α, IKK-βand IκB-β, increases expression of IκB-α, and suppresses nuclear translocation of NF-κB and its DNA binding activity. Dephosphorylation of NF-κB upstream regulators PI3K, Akt and PDK1 is also displayed. In addition, activation of caspase-8, change of mitochondrial membrane potential, release of cytochrome c and Smac/DIABLO, and activation of caspase-9 and -3 are observed at the early time point. Downregulation in the expression of Ku70 and XIAP is exhibited afterward. Morusin suppresses viability of prostate cancer cells, but little effect in normal human prostate epithelial cells. Morusin also reduces STAT3 activity by inhibiting its phosphorylation, nuclear accumulation, and DNA binding activity. In addition, morusin down-regulated expression of STAT3 target genes encoding Bcl-xL, Bcl-2, Survivin, c-Myc and Cyclin D1. It induces apoptosis in human prostate cancer cells by reducing STAT3 activity.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Mulberrochromene

Similar Products

  • Morusin [orb1301282]

    99.72%

    62596-29-6

    420.45

    C25H24O6

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Morusin (orb1221943)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
5 mg
$ 110.00
10 mg
$ 160.00
25 mg
$ 240.00
50 mg
$ 340.00
100 mg
$ 490.00